| Name | Title | Contact Details |
|---|
Arzeda The Protein Design Company is a synthetic biology company.
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Using artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, we are accelerating the discovery of proteins...
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Smith-Sterling Dental Laboratories is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.